RCKT

Rocket Pharmaceuticals Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth 4/10
  • Momentum 3/10
Rocket Pharmaceuticals sales and earnings growth
RCKT Growth
Neutral
  • Revenue Y/Y 0.00%
  • EPS Y/Y 17.58%
  • FCF Y/Y -0.23%
Rocket Pharmaceuticals gross and profit margin trends
RCKT Profitability
Low
  • Gross margin 0.00%
  • EPS margin 0.00%
  • ROIC -83.00%
Rocket Pharmaceuticals net debt vs free cash flow
RCKT Risk
Great
  • Debt / Equity 0.1
  • Debt / FCF 0.0
  • Interest coverage -126.4

Rocket Pharmaceuticals stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗